Prescriptive changes for price reduction of older medicines

4 December 2023 - Changes to the Dental and Pharmaceutical Benefits Agency's regulations and general advice on the pricing of ...

Read more →

Savings from side deals higher than previously forecast

17 November 2023 - The TLV estimates that the pharmaceutical companies will pay approximately SEK 3.33 billion in reimbursement for 2023 ...

Read more →

Basic health insurance to cover test that can predict return of breast cancer

30 October 2023 - A special test that predicts the chance of hormone-sensitive breast cancer returning will be added to ...

Read more →

Health economic assessment of Spinraza for type 5q spinal muscular atrophy

18 October 2023 - TLV has produced a health economic knowledge base for the regions for Spinraza (nusinersen sodium) for the ...

Read more →

Health economic assessment of Beyfortus for the prevention of lower respiratory tract disease caused by respiratory syncytial virus

18 October 2023 - TLV has prepared a health economic assessment for the regions for the medicine Beyfortus (nirsevimab).  ...

Read more →

Health economic assessment of Enhertu in breast cancer

13 October 2023 - TLV has produced a health economic assessment of Enhertu (trastuzumab deruxtecan) for the regions.  ...

Read more →

Health economic assessment of the gene therapy Hemgenix in severe and moderate haemophilia B

11 October 2023 - TLV has developed a health economic knowledge base for the regions for the gene therapy Hemgenix (etranacogene ...

Read more →

Patient access to medicines for rare health conditions at sustainable costs can be strengthened

2 October 2023 - The Swedish Dental and Medicines Benefits Agency, TLV, today submits a report to the government on how ...

Read more →

TLV believes that the requirements for evidence in new EU legislation must be strengthened

9 October 2023 - The European Commission's proposal for a new regulation and directive has a decisive impact on the quality ...

Read more →

New payment models are needed to finance new advanced treatments

29 September 2023 - Pricing and subsidy methods and processes need to be developed to address the challenges that arise when ...

Read more →

TLV is tasked with carrying out health economic assessments of new drugs against cancer

4 July 2023 - The TLV shall carry out health economic assessments of new drugs to be used in clinics, ...

Read more →

Imbruvica is included in the high-cost protection with a changed benefit limitation

19 June 2023 - Ibrutinib (Imbruvica)140 mg, 280 mg & 420 mg tablets are now subsidised for the treatment ...

Read more →

More measures are needed to curb the development cost of pharmaceuticals

16 June 2023 - There are more and more new drugs, and more people are receiving treatment for their illnesses. At ...

Read more →

Health economic assessment of Carvykti in the treatment of multiple myeloma

16 June 2023 - TLV has prepared a health economic assessment for the regions for Carvykti (ciltacabtagene autoleucel). ...

Read more →

Health economic assessment of Pluvicto in advanced prostate cancer

12 June 2023 - TLV has produced a health economic assessment for the regions for Pluvicto (Lutetium Lu 177 vipivotide tetraxetan).  ...

Read more →